Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. reports an amended joint Schedule 13G/A disclosing ownership by Opaleye-affiliated filers. The Reporting Persons state beneficial ownership of 2,620,369 shares, representing 12.03% of common stock. The filing attributes 2,530,369 shares (11.62%) to Opaleye, L.P. and notes the holdings include shares in a managed account over which voting and dispositive power are shared.
Alpha Cognition Inc. Chief Operating Officer Lauren D'Angelo bought 3,500 Common Shares in an open-market purchase at $5.76 per share. This transaction increased her direct ownership to 140,695 shares, representing a modest expansion of her personal stake in the company.
Opaleye Management Inc., a more than 10% owner of Alpha Cognition Inc., reported additional indirect open-market purchases of the company’s common stock. Through Opaleye, L.P., it bought 17,395 shares at a weighted average price of $5.6926 on May 18 and 16,648 shares at $5.8257 on May 15, for a total of 34,043 shares. Following these trades, Opaleye, L.P. held 2,505,993 shares, and a separately managed account overseen by Opaleye held 90,000 shares. The filing notes that Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. reported first-quarter 2026 results showing early commercial traction but higher losses. Total revenue was $3.53 million, up 21% year over year, driven by a jump in ZUNVEYL product sales to $3.50 million, while licensing revenue fell to $0.03 million.
Operating expenses rose to $11.63 million, mainly from expanding sales, marketing, and headcount to support the ZUNVEYL launch, resulting in a net loss of $6.48 million versus $1.73 million a year earlier. Cash and cash equivalents were $54.25 million, and management believes this is sufficient for at least 12 months, though additional capital will likely be needed for ongoing commercialization and R&D.
The company disclosed a material weakness in internal control over financial reporting related to complex instruments and segregation of duties and is implementing enhanced review procedures and external technical support. Alpha Cognition remains focused on building the ZUNVEYL franchise and advancing its preclinical neurodegenerative pipeline.
Alpha Cognition Inc. files Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership stakes held by affiliated entities and individuals. The filing lists Manchester Management Company, LLC with 919,935 shares (4.2%), Manchester Management PR, LLC with 919,935 shares (4.2%), James E. Besser with 1,076,935 shares (4.9%), and Morgan C. Frank with 888,935 shares (4.0%).
The filing states that all reported securities are directly owned by advisory clients of Manchester Management PR, LLC and includes a Joint Filing Agreement. The signatures are dated 05/12/2026.
Alpha Cognition Inc. amendment to a joint Schedule 13G/A reports that Opaleye-linked reporting persons beneficially own 2,561,950 shares of common stock, representing 11.77% of the class. The filing attributes shared voting and dispositive power over those shares, and cites 21,774,104 shares outstanding as of 03/31/2026 from Alpha Cognition's Form 10-K.
The statement is filed jointly by Opaleye Management Inc., Opaleye, L.P., and James Silverman and clarifies the adviser/fund relationship and voting/dispositive arrangements for the reported holdings.
Alpha Cognition Inc. filed an amended report to update details about director Bethany Sensenig’s board roles. On April 28, 2026, the Board appointed her to the Audit Committee and the Governance and Nomination Committee. Following the annual meeting of shareholders on June 16, 2026, she will become Chair of the Audit Committee.
Alpha Cognition Inc. is asking shareholders at its June 16, 2026 annual meeting in Texas to fix the Board size at six directors, elect six nominees, and approve CBIZ CPAs P.C. as independent auditors for the year ending December 31, 2026.
Current chair Len Mertz will not stand for re-election, and the Board has selected Robert Wills to become the next non-executive chair. The proxy details ownership of 21,774,104 common shares and 316,655 Class B preferred Series A shares as of April 24, 2026, with directors and officers holding 8.6% of common shares and 9.5% of total voting stock.
The filing outlines governance practices, Board and committee composition, audit committee qualifications, and compensation for key executives, including 2025 total pay of $3.6 million for CEO Michael McFadden and $2.4 million for COO Lauren D’Angelo. It also describes the 2025 transition of audit work from Manning Elliott to CBIZ, characterized as an administrative change following the move of principal offices to Texas with no reported disagreements on accounting or auditing matters.
Alpha Cognition Inc. appointed Bethany Sensenig to its board of directors effective April 15, 2026. She brings senior finance and operations experience from roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and a 13-year career at Biogen with P&L responsibility over about $1 billion in annual revenue across 30 countries.
As a non-employee director, she will be compensated under the company’s standard policy and received an initial equity grant of 5,489 restricted stock units and 6,991 stock options, with an exercise price of $6.65 per share. Both the RSUs and options vest one year after the grant date. The company states there are no arrangements, family relationships, or related-party transactions linked to her appointment.
Alpha Cognition Inc. director Bethany Sensenig reported equity awards consisting of stock options and restricted stock units as compensation. She received 6,991 Common Share Options at an exercise price of $6.65 per share, expiring on April 16, 2036, which will vest one year from the grant date. She also received 5,489 Common Shares in the form of restricted stock units that vest one year from the grant date. After these awards, her reported holdings are 6,991 options and 5,489 common shares held directly, and there were no open-market purchases or sales in this filing.